Request More Information Contact the Seller

  • RE:  Bio Technology Company
  • Contact:  Jason Flowers

Quick Facts

Asking Price: $5,000,000
Annual Revenue: $826,081
Net Profit: Not Disclosed
Cash Flow: $33,031
Total Debt: Not Disclosed
FF&E: Not Disclosed
Real Estate: Not Disclosed
Year Established: 2011
Employees: 2
BBN Listing #: 76204955
Broker Reference #: 2603-17858

Email or Print Listing

Business Overview:

This firm develops life science research tools enabling autonomous, non-invasive, real-time monitoring of compound bioavailability, biological events, or viability/metabolic dynamics from any cell using a proprietary synthetic luciferase technology that does not require external stimulation to function. The Company’s products are immediately relevant to discovery phase pharmacology programs as an improved method for accessing the toxicity and metabolic impact of potential new drug compounds and to in vitro and in vivo basic research and development activities for interrogating tumor formation, progression, and recession, cellular health, motility, localization, or transcriptional activity. Their patent protected synthetic luciferase removes the need for external stimulation that limits current fluorescent and bioluminescent imaging approaches. Unlike previous technologies, it can automatically turn on or off light production to indicate biomarker transcription or changes in differentiation state, continuously emit harmless visible light to enable persistent localization and viability tracking, or autonomously adjust signal intensity to reflect real-time changes in metabolism, toxicity, or any other desired cellular metric. This solves the problems of uneven excitation and emission in 3D culture applications, allows the distribution, health, and propagation of implanted cells to be tracked in real-time in small animal models, and removes the need to sacrifice precious in vitro samples concurrent with luciferin exposure. As a simple genetic technology, their synthetic luciferase can be delivered using the same transfection approaches as older fluorescent/luminescent genes and expression can be regulated using any transcriptional or synthetic biology control architecture. This drop-in replacement capability, combined with improved functionality, enables exciting new capabilities, and accelerates existing research by producing more data, reducing costs, and enabling continuous automated tracking without requiring perturbation at any point throughout the data collection process.

The purchase of this company includes patents, ready-to-ship product inventory, the bacterial stocks required to make more of the products, all scientific lab notebooks from R&D operations, and company intelligence data. The value is based on the 'cost to recreate' and projections based on requests. The products are ready for orders and in demand by some of the world’s largest biotech companies and most respected researchers. This company has recently completed the vetting process to have their products featured in the Thermo Fisher Scientific catalogue. A key element necessary for growth and marketing of the products is an experienced business development team. Orders can be worth $1mm each large client within the first 5 years.

To request more information regarding this listing, simply check the ADD TO REQUEST INFO BASKET button and when you are done searching and have made all your selections, simply click on the REQUEST INFO button at the bottom of the page.

Property Features and Assets:

This business is relocatable! Assets = $778,000

Market Competition and Expansion:

The company competes with single-data-point bioluminescent technologies from 2 companies; expensive equipment-based technologies from 1 competitor; and older fluorescent assay technologies from a major healthcare company and a variety of small vendors. None of these technologies can offer advanced data production at the throughput level or price point of this company's autobioluminescent technology. There is strong potential for growth. Prior to The Company’s development of their continuous bioluminescent synthetic luciferase there were no significant advancements in bioluminescent technologies for over 20 years. They developed the first product on the market to offer multiple data points from a single sample and the only reporter system capable of automatic self-control.

Reason for Selling:

Selling was part of the company's exit strategy.

Additional Details:

  • The property is Leased.
  • The owner is willing to train/assist the new owner.
  • This is not homebased business opportunity.
  • This is not a franchise resale opportunity

Relevant Links:

Request More Information

BusinessBroker.net is one of the largest business for sale marketplaces in the world that connects tens-of-thousands of business buyers and sellers every month. Sell a Business Online or if you’re a broker or a commercial agent sign up for a Business Broker Membership today!

    Add Businesses and/or Franchises
    To Basket For Free Information

    This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our cookies information for more details.